Loading...
SCNI logo

Scinai Immunotherapeutics Ltd.NasdaqCM:SCNI Stock Report

Market Cap US$1.8m
Share Price
US$0.45
My Fair Value
n/a
1Y-83.5%
7D-2.4%
1D
Portfolio Value
​
View

Scinai Immunotherapeutics Ltd.

NasdaqCM:SCNI Stock Report

Market Cap: US$1.8m

Scinai Immunotherapeutics (SCNI) Stock Overview

Operates as a biopharmaceutical company in Israel and internationally. More details

SCNI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($2M)

Does not have meaningful revenue ($1M)


SCNI Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Scinai Immunotherapeutics Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Scinai Immunotherapeutics
Historical stock prices
Current Share PriceUS$0.45
52 Week HighUS$6.18
52 Week LowUS$0.41
Beta2.19
1 Month Change-36.96%
3 Month Change-49.36%
1 Year Change-83.46%
3 Year Change-97.35%
5 Year Change-99.85%
Change since IPO-99.89%

Recent News & Updates

Recent updates

Analysis Article • Dec 15

This Is Why Scinai Immunotherapeutics Ltd.'s (NASDAQ:SCNI) CEO Compensation Looks Appropriate

Key Insights Scinai Immunotherapeutics to hold its Annual General Meeting on 22nd of December Total pay for CEO Amir...
Analysis Article • Nov 29

Why Scinai Immunotherapeutics' (NASDAQ:SCNI) Healthy Earnings Aren’t As Good As They Seem

Shareholders were pleased with the recent earnings report from Scinai Immunotherapeutics Ltd. ( NASDAQ:SCNI...
Analysis Article • Nov 10

Here's Why BiondVax Pharmaceuticals (NASDAQ:BVXV) Can Afford Some Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Aug 25

Bionvax Pharmaceuticals GAAP EPS of -NIS0.02

Biondvax Pharmaceuticals press release (NASDAQ:BVXV): Q2 GAAP EPS of -NIS0.02. As of June 30, 2022, BiondVax had cash and cash equivalents of NIS39.5M ($11.3 million) compared to NIS 54.0M as of December 31, 2021.
Seeking Alpha • Aug 10

BiondVax, European Investment Bank agree on new terms to co's outstanding €24M loan

BiondVax Pharmaceuticals (NASDAQ:BVXV) on Wednesday said the European Investment Bank (EIB) had formally approved new terms to the outstanding €24M loan to the Israeli biopharmaceutical company. The new terms include: An extension of the maturity dates from 2023 and 2024 to Dec. 2027. Interest on the loan beginning to accrue only from Jan. 1, 2022 at an annual rate of 7%, though it has been outstanding since 2018. Variable renumeration to the EIB in the form of royalties from BVXV until the bank gets the higher of a total of 2.8x the original €24M principal and 20% internal rate of return on the principal calculated from Jan. 1. A prepayment indemnity clause and a principal repayment clause. Jerusalem-based BiondVax develops antibody therapies targeting diseases such as COVID-19, asthma and psoriasis. U.S.-listed shares of BVXV +0.8% to $1.26 in morning trading.
Analysis Article • Mar 31

We Think BiondVax Pharmaceuticals (NASDAQ:BVXV) Has A Fair Chunk Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

SCNIUS BiotechsUS Market
7D-2.4%1.1%1.5%
1Y-83.5%35.8%28.6%

Return vs Industry: SCNI underperformed the US Biotechs industry which returned 33% over the past year.

Return vs Market: SCNI underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is SCNI's price volatile compared to industry and market?
SCNI volatility
SCNI Average Weekly Movement22.4%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: SCNI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SCNI's weekly volatility has increased from 17% to 22% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200345Amir Reichmanwww.scinai.com

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies.

Scinai Immunotherapeutics Ltd. Fundamentals Summary

How do Scinai Immunotherapeutics's earnings and revenue compare to its market cap?
SCNI fundamental statistics
Market capUS$1.78m
Earnings (TTM)-US$8.31m
Revenue (TTM)US$1.31m
1.4x
P/S Ratio
-0.2x
P/E Ratio

Is SCNI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SCNI income statement (TTM)
RevenueUS$1.31m
Cost of RevenueUS$3.96m
Gross Profit-US$2.65m
Other ExpensesUS$5.66m
Earnings-US$8.31m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.10
Gross Margin-202.29%
Net Profit Margin-633.64%
Debt/Equity Ratio3.6%

How did SCNI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/29 12:08
End of Day Share Price 2026/05/29 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Scinai Immunotherapeutics Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation
David BautzZacks Small-Cap Research